CAC
TERN

Cowen and Company’s Terns Pharmaceuticals TERN Stock Holding History

Cowen and Company’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-85,000
Closed -$252K – 750
2022
Q1 		$252K Hold
85,000
– – 0.02% 218
2021
Q4 		$601K Hold
85,000
– – 0.05% 203
2021
Q3 		$886K Hold
85,000
– – 0.04% 156
2021
Q2 		$1.04M Buy
85,000
+60,000
+240% +$1.02M 0.05% 121
2021
Q1 		$550K Buy
+25,000
New +$548K 0.04% 181

Other funds holding TERN

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Cowen and Company's TERN Position: Q2 2022 in Review

Cowen and Company sold out of Terns Pharmaceuticals (TERN) in Q2 2022, closing a stake of 85,000 shares — an estimated $252K sold.

Cowen and Company first reported a position in TERN in Q1 2021 and held it in 5 quarters. The position peaked at $1.04M in Q2 2021. 42 funds tracked by Wall St. Rank hold TERN as of Q2 2022.

  • Cowen and Company reported no remaining Terns Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Cowen and Company sold 85,000 Terns Pharmaceuticals shares in Q2 2022, an estimated $252K.
  • Cowen and Company first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Cowen and Company's Terns Pharmaceuticals position peaked at $1.04M in Q2 2021.
  • 42 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2022.

Based on Cowen and Company's 13F filing for Q2 2022, filed 5 Aug 2022.